Table 1.
Demographic characteristics | |
Gender, n (%) | |
Male | 237 (57.8%) |
Females | 173 (42.2%) |
Age, median (IQR), months | 1.9 (1.1–3.9) |
Weight at admission, median (IQR), kg | 4.8 (3.9–6.2) |
Prematurity (gestational age <37 weeks), n (%) | 67 (16.3%) |
Underlying chronic conditions, n (%) | 34 (8.3%) |
CHD, n (%)1 | 12 (35.3%) |
BPD, n (%)1 | 10 (29.4%) |
Polymalformative syndrome or chromosomopathy,2 n (%)1 | 8 (23.5%) |
Severe neurologic impairment, n (%)1 | 4 (11.8%) |
Disease characteristics | |
Admission | |
PICU, n (%) | 58 (14.1%) |
Pediatric ward, n (%) | 352 (85.9%) |
Length of stay, median (IQR), days | 4.0 (3.0–7.0) |
Supplemental oxygen, n (%) | 327 (79.8%) |
Days of oxygen use, median (IQR), days | 3 (1–5) |
Apnea, n (%) | 24 (5.9%) |
Fever,3 n (%) | 168 (41%) |
Radiologic evaluation, n (%) | |
No performed | 221 (53.9%) |
No pathologic findings or peribronquial infiltrates without consolidation or atelectasis | 79 (19.3%) |
Peribronquial infiltrates with mild‐to‐moderate consolidation or atelectasis | 76 (18.5%) |
Extensive consolidation or atelectasis | 34 (8.3%) |
BCS at admission, median (IQR), points | 7 (5–9) |
Highest BCS during the inpatient management, median (IQR), points | 8 (6–10) |
IQR, interquartile range; BPD, bronchopulmonary dysplasia; CHD, congenital heart disease; PICU, pediatric intensive care unit; BCS, bronchiolitis clinical score.
Numbers in parentheses represent the percentage calculated for patients with an underlying chronic illness.
Two patients with Down syndrome (sd), craneofacial malformation with facial and subglotic angioma, polymalformative sd without specific diagnosis (Pierre–Robin sequence, arthrogryposis, trombocytopenia, interventricular defect, ventriculomegaly), CHARGE sd, Branchio‐otic (BO) sd, Rubinstein–Taybi sd, and polymalformative sd without specific diagnosis (anorectal malformation, congenital diaphragmatic hernia, aortic arch hypoplasia).
Temperature ≥38°C at admission or the 48 hr before.
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.